Paul Barr, MD: Additional Chemo-Immunotherapy

preview_player
Показать описание
Paul Barr, MD, assistant professor of Medicine, University of Rochester Medical Center, director of the Clinical Trials Office, Wilmot Cancer Center, discusses a 63-year-old retired civil engineer from Houston, Texas.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
Paul Barr, MD: 0:01:27

Paul Barr, MD: Additional Chemo-Immunotherapy

Paul Barr, MD: 0:01:30

Paul Barr, MD: Dose Intensity

Paul Barr, MD: 0:02:01

Paul Barr, MD: Treatment Options for Patients With Previously Treated CLL

Paul Barr, MD: 0:01:37

Paul Barr, MD: Significance of Treating to Progression

Paul Barr, MD: 0:01:37

Paul Barr, MD: Options to Prolong Survival

Paul Barr, MD: 0:01:07

Paul Barr, MD: Bendamustine/Rituximab Therapy

Paul Barr, MD: 0:01:55

Paul Barr, MD: Principle Treatment Options for Patients With a 17p Deletion

Paul Barr, MD: 0:03:16

Paul Barr, MD: Relapse Following Purine Analog Therapy

Paul Barr, MD: 0:01:11

Paul Barr, MD: Phase III Data to Support Usage of Bruton's TKIs

Paul Barr, MD: 0:02:55

Paul Barr, MD: Use of Bruton's Tyrosine Kinase Inhibitor

Paul M. Barr, 0:01:55

Paul M. Barr, MD, elaborates on outcomes from the RESONATE trial in relapsed/refractory CLL

Paul M. Barr, 0:01:59

Paul M. Barr, MD, offers opinion on ibrutinib in 1st line chronic lymphocytic leukemia

Is Maintenance Therapy 0:02:00

Is Maintenance Therapy with Rituximab for Follicular Lymphoma a Good Idea?

Paul M. Barr, 0:02:13

Paul M. Barr, MD, considers the role of CAR-T therapy in B-cell lymphomas

Front-Line Chemoimmunotherapy in 0:05:35

Front-Line Chemoimmunotherapy in Chronic Lymphocytic Leukemia

Debate: Best Approach 0:11:23

Debate: Best Approach for Multiple Relapsed CLL after Chemoimmunotherapy - Kinase inhibitor

Phase 1b trial 0:01:56

Phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory CLL

Debate: Optimal approach 0:13:55

Debate: Optimal approach for the management of CLL patients with del(17p) - Novel Agents

The latest CLL 0:50:25

The latest CLL treatments and therapies with Dr Jan Burger

New Advances in 0:21:04

New Advances in Therapies for Chronic Lymphocytic Leukemia CLL

CLL Prognosis and 0:04:43

CLL Prognosis and Treatment Options

Medicine Grand Rounds: 0:51:50

Medicine Grand Rounds: 'Checkpoint Blockade in Classical Hodgkin Lymphoma' 2/23/21

Frontline Treatment for 0:04:10

Frontline Treatment for Newly Diagnosed Follicular Lymphoma

Dr. Anthony Mato 0:01:29

Dr. Anthony Mato on the Difference Between Intolerance and Resistance in CLL

welcome to shbcf.ru